395 related articles for article (PubMed ID: 8961487)
1. Results of postchemotherapy adjunctive retroperitoneal lymph node dissection in non-seminomatous germ cell cancer patients.
Goepel M; Recker F; Otto T; Krege S; Rübben H
Urol Int; 1996; 57(4):209-12. PubMed ID: 8961487
[TBL] [Abstract][Full Text] [Related]
2. Retroperitoneal lymph node dissection as adjuvant therapy in the treatment of non-seminomatous testicular cancer.
Thijssens K; Vaneerdeweg W; Schrijvers D; Eyskens E; Van Oosterom A
Acta Chir Belg; 2003; 103(6):599-602. PubMed ID: 14743567
[TBL] [Abstract][Full Text] [Related]
3. Resection of postchemotherapy residual masses and limited retroperitoneal lymphadenectomy in patients with metastatic testicular nonseminomatous germ cell tumors.
Aprikian AG; Herr HW; Bajorin DF; Bosl GJ
Cancer; 1994 Aug; 74(4):1329-34. PubMed ID: 8055456
[TBL] [Abstract][Full Text] [Related]
4. [Efficacy of modified retroperitoneal lymph node dissection for testicular nonseminomatous germ cell tumors].
Liu ZW; Zhou FJ; Han H; Qin ZK; Yu SL; Li YH; Ye YL; Teng XY
Ai Zheng; 2008 Dec; 27(12):1302-6. PubMed ID: 19079998
[TBL] [Abstract][Full Text] [Related]
5. [Clinical outcome of postchemotherapy retroperitoneal lymph node dissection and predicting retroperitoneal histology in advanced nonseminomatous germ cell tumours of the testis].
Li XD; Guo SJ; Chen SL; Liu ZF; Dong P; Zhang ZL; Jiang LJ; Yao K; Li YH; Han H; Qin ZK; Liu ZW; Zhou FJ
Zhonghua Wai Ke Za Zhi; 2017 Aug; 55(8):603-607. PubMed ID: 28789511
[No Abstract] [Full Text] [Related]
6. Comparison of histological results from the resection of residual masses at different sites after chemotherapy for metastatic non-seminomatous germ cell tumours.
Hartmann JT; Candelaria M; Kuczyk MA; Schmoll HJ; Bokemeyer C
Eur J Cancer; 1997 May; 33(6):843-7. PubMed ID: 9291803
[TBL] [Abstract][Full Text] [Related]
7. Teratoma in primary testis tumor reduces complete response rates in the retroperitoneum after primary chemotherapy. The case for primary retroperitoneal lymph node dissection of stage IIb germ cell tumors with teratomatous elements.
Rabbani F; Gleave ME; Coppin CM; Murray N; Sullivan LD
Cancer; 1996 Aug; 78(3):480-6. PubMed ID: 8697394
[TBL] [Abstract][Full Text] [Related]
8. Survival of patients with viable malignant non-seminomatous germ cell tumour persistent after cisplatin-based induction chemotherapy.
Hollender A; Stenwig EA; Ous S; Fosså SD
Eur Urol; 1997; 31(2):141-7. PubMed ID: 9076455
[TBL] [Abstract][Full Text] [Related]
9. RPLND or primary chemotherapy in clinical stage IIA/B nonseminomatous germ cell tumors? Results of a prospective multicenter trial including quality of life assessment.
Weissbach L; Bussar-Maatz R; Flechtner H; Pichlmeier U; Hartmann M; Keller L
Eur Urol; 2000 May; 37(5):582-94. PubMed ID: 10765098
[TBL] [Abstract][Full Text] [Related]
10. Post-chemotherapy residual mass in non-seminomatous testicular cancer. The role of retroperitoneal lymph node dissection.
El Sayed S; Grando JP; Almeida SH; Mortati Neto N; Moreira HA
Int Braz J Urol; 2004; 30(5):384-8. PubMed ID: 15610570
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant bleomycin, etoposide and cisplatin in pathological stage II non-seminomatous testicular cancer. the Indiana University experience.
Behnia M; Foster R; Einhorn LH; Donohue J; Nichols CR
Eur J Cancer; 2000 Mar; 36(4):472-5. PubMed ID: 10717522
[TBL] [Abstract][Full Text] [Related]
12. Delayed orchiectomy after chemotherapy in patients with advanced testicular cancer.
Ondrus D; Hornák M; Breza J; Mat'oska J; Schnorrer M; Belan V; Kausitz J
Int Urol Nephrol; 2001; 32(4):665-7. PubMed ID: 11989561
[TBL] [Abstract][Full Text] [Related]
13. The impact of bleomycin on retroperitoneal histology at post-chemotherapy retroperitoneal lymph node dissection of good risk germ cell tumors.
Cary KC; Pedrosa JA; Kaimakliotis HZ; Masterson TA; Einhorn LH; Foster RS
J Urol; 2015 Feb; 193(2):507-12. PubMed ID: 25254937
[TBL] [Abstract][Full Text] [Related]
14. Sequential resection of residual abdominal and thoracic masses after chemotherapy for metastatic non-seminomatous germ cell tumours.
Gerl A; Clemm C; Schmeller N; Dienemann H; Weiss M; Kriegmair M; Löhrs U; Wilmanns W
Br J Cancer; 1994 Nov; 70(5):960-5. PubMed ID: 7524606
[TBL] [Abstract][Full Text] [Related]
15. Improved management of abdominal undescended testicular tumors with bulky confluent retroperitoneal nodal metastases.
Kulkarni JN; Desai SM; Phadke GK; Tongaonkar HB
J Urol; 1996 Oct; 156(4):1341-4. PubMed ID: 8808867
[TBL] [Abstract][Full Text] [Related]
16. Postchemotherapy retroperitoneal surgery remains necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses.
Oldenburg J; Alfsen GC; Lien HH; Aass N; Waehre H; Fossa SD
J Clin Oncol; 2003 Sep; 21(17):3310-7. PubMed ID: 12947067
[TBL] [Abstract][Full Text] [Related]
17. Is modified retroperitoneal lymph node dissection (MRLND) still feasible in the treatment of patients with clinical stage I non-seminomatous testicular cancer?
Sosnowski M; Jeromin L; Płuzańska A
Int Urol Nephrol; 1994; 26(4):471-7. PubMed ID: 7528180
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant surgery in testicular cancer patients undergoing postchemotherapy retroperitoneal lymph node dissection.
Djaladat H; Nichols C; Daneshmand S
Ann Surg Oncol; 2012 Jul; 19(7):2388-93. PubMed ID: 22395993
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin-based chemotherapy after retroperitoneal lymph node dissection in patients with pathological stage II nonseminomatous germ cell tumors.
Culine S; Theodore C; Farhat F; Bekradda M; Terrier-Lacombe MJ; Droz JP
J Surg Oncol; 1996 Mar; 61(3):195-8. PubMed ID: 8637206
[TBL] [Abstract][Full Text] [Related]
20. Primary and Postchemotherapy Retroperitoneal Lymphadenectomy for Testicular Cancer.
Heidenreich A; Paffenholz P; Nestler T; Pfister D
Oncol Res Treat; 2018; 41(6):370-378. PubMed ID: 29772568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
